Mast Cell Activation Syndrome (MCAS) Overview
Learn About Mast Cell Activation Syndrome (MCAS)
- Mast cell activation syndrome
- MCAS
MD Anderson
Prithviraj Bose is a Hematologist Oncology specialist and a Hematologist in Houston, Texas. Dr. Bose and is rated as an Elite provider by MediFind in the treatment of Mast Cell Activation Syndrome (MCAS). His top areas of expertise are Myelofibrosis, Essential Thrombocythemia, Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.
Srdan Verstovsek is an Oncologist and a Hematologist Oncology provider in Houston, Texas. Dr. Verstovsek and is rated as a Distinguished provider by MediFind in the treatment of Mast Cell Activation Syndrome (MCAS). His top areas of expertise are Myelofibrosis, Essential Thrombocythemia, Polycythemia Vera, Bone Marrow Aspiration, and Bone Marrow Transplant.
University Of Texas Health Science Center At San Antonio
Robyn Scherber is a Hematologist in San Antonio, Texas. Dr. Scherber and is rated as a Distinguished provider by MediFind in the treatment of Mast Cell Activation Syndrome (MCAS). Her top areas of expertise are Myeloproliferative Neoplasms (MPN), Polycythemia Vera, Myelofibrosis, Essential Thrombocythemia, and Bone Marrow Transplant. Dr. Scherber is currently accepting new patients.
Summary: The primary objective of the rollover study is to evaluate the long-term safety of avapritinib in participants who have completed a Blueprint Medicines sponsored study (parent study) and continued to benefit from avapritinib.
Summary: Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) is a challenging disease to treat. Targeted KIT inhibitors have been approved for this indication based on their ability to control the mastocytosis portion of the disease, but patients frequently experience progression of the concomitant myeloid malignancy (i.e. the AHN). Using a combination approach to treat both aspects of t...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center